


**Product Name** : Lucerastat  
**Cat. No.** : PC-61429  
**CAS No.** : 141206-42-0  
**Molecular Formula** : C<sub>10</sub>H<sub>21</sub>NO<sub>4</sub>  
**Molecular Weight** : 219.281  
**Target** : Other Targets  
**Solubility** : 10 mM in DMSO



## Biological Activity

Lucerastat (NB-DGJ, ACT-434964) is a galactose analogue that is an **UDP-glucose ceramide glucosyltransferase (UGCG/GCS)** inhibitor (IC<sub>50</sub>=41.4 uM).

Lucerastat prevents glucosylceramide biosynthesis both in vitro and in mouse models of lysosome storage disorders, without affecting α-glucosidase I and II or β-glucocerebrosidase (IC<sub>50</sub>>1 mM).

Lucerastat shows potential as substrate reduction therapy for glycolipid storage disorders such as Gaucher disease and Fabry disease.

## References

Platt FM, et al. *J Biol Chem.* 1994 Oct 28;269(43):27108-14.

Andersson U, et al. *Biochem Pharmacol.* 2000 Apr 1;59(7):821-9.

Kasperzyk JL, et al. *J Neurochem.* 2004 May;89(3):645-53.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com